Benitec Biopharma Ltd ADR

Yahoo Finance • 5 days ago

Benitec GAAP EPS of -$1.05 beats by $0.72

* Benitec press release [https://seekingalpha.com/pr/20240290-benitec-biopharma-releases-full-year-2025-financial-results-and-provides-operational-update] (NASDAQ:BNTC [https://seekingalpha.com/symbol/BNTC]): FY GAAP EPS of -$1.05 beats... Full story

Yahoo Finance • 5 days ago

Benitec Biopharma files $200M mixed securities shelf

* Benitec Biopharma (NASDAQ:BNTC [https://seekingalpha.com/symbol/BNTC]) filed $200M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10439771] MORE ON BENITEC * Seeking Alpha’s Quant Rating on Benitec [https://see... Full story

Yahoo Finance • 5 days ago

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment StudyExpected in Q4 2025 HAYWARD, Calif., Sept... Full story

Yahoo Finance • 19 days ago

Amkor Technology Reaches Analyst Target Price

In recent trading, shares of Amkor Technology Inc. (Symbol: AMKR) have crossed above the average analyst 12-month target price of $41.00, changing hands for $41.19/share. When a stock reaches the target an analyst has set, the analyst log... Full story

Yahoo Finance • 2 months ago

Benitec Biopharma's SWOT analysis: gene therapy stock shows promise amid clinical progress

Benitec Biopharma Inc. (NASDAQ:BNTC), a biotechnology company specializing in gene therapies, has been making significant strides in its clinical development programs, particularly with its lead candidate BB-301 for the treatment of oculo... Full story

Yahoo Finance • 3 months ago

Benitec BioPharma stock maintains Market Outperform rating at JMP

Investing.com - Benitec BioPharma (NASDAQ:BNTC), currently trading at $13.84, maintained its Market Outperform rating and $20.00 price target in a research note from JMP Securities on Thursday. According to InvestingPro data, analysts’ tar... Full story

Yahoo Finance • 3 months ago

Cowen initiates Benitec BioPharma stock with Buy rating on OPMD treatment

Investing.com - TD Cowen initiated coverage on Benitec BioPharma (NASDAQ:BNTC) with a Buy rating on Monday. The clinical-stage biotechnology company, currently valued at $346 million, has seen its shares surge over 12% in the past week. T... Full story

Yahoo Finance • 6 months ago

Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with... Full story

Yahoo Finance • 7 months ago

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scienti... Full story

Yahoo Finance • 2 years ago

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propriet... Full story

Yahoo Finance • 2 years ago

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary... Full story

Yahoo Finance • 2 years ago

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

HAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary... Full story

Yahoo Finance • 2 years ago

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propriet... Full story

Yahoo Finance • 2 years ago

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary... Full story

Yahoo Finance • 2 years ago

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietar... Full story

Yahoo Finance • 3 years ago

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprieta... Full story

Yahoo Finance • 3 years ago

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propr... Full story

Yahoo Finance • 3 years ago

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propr... Full story

Yahoo Finance • 3 years ago

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its prop... Full story

Yahoo Finance • 3 years ago

Benitec Biopharma Releases Q3 2022 Financial Results

HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propri... Full story